Zoonoses

Immunocore announces publication of preclinical data in Hepatology showing the potential of ImmTAV® bispecific molecules for functional cure of chronic hepatitis B

Retrieved on: 
Thursday, August 27, 2020
Medical specialties, Clinical medicine, Medicine, Immune system, Immunology, Infectious causes of cancer, Pandemics, Virus, Zoonoses, Hepatitis B, T cell, ImmTAC

Additionally, HBV-specific immune responses in people living with Hepatitis B are often exhausted, making it difficult for them to eliminate the infected cells.

Key Points: 
  • Additionally, HBV-specific immune responses in people living with Hepatitis B are often exhausted, making it difficult for them to eliminate the infected cells.
  • With this in mind, the team at Immunocore is utilising its immunemobilising monoclonal T cell receptors against virus (ImmTAV) platform to address these challenges.
  • ImmTAV and ImmTAC molecules resemble each other in appearance and function, although ImmTAV molecules are designed to specifically recognise and kill virally infected cells.
  • Immunocore is headquartered at Milton Park, Oxfordshire, UK, with offices in Conshohocken, Pennsylvania and Rockville, Maryland in the US.

Global Virus Network Reports: Renowned Doherty Institute In Australia Independently Verifies Earlier Findings That An Antimicrobial Technology Eradicates SARS-CoV-2 On Surfaces For More Than Six Weeks

Retrieved on: 
Thursday, August 27, 2020
Sarbecovirus, Zoonoses, Animal diseases, Respiratory diseases, Severe acute respiratory syndrome coronavirus 2, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome

The announcement was made today by Dr. Christian Brchot, President of the GVN.

Key Points: 
  • The announcement was made today by Dr. Christian Brchot, President of the GVN.
  • Proving the longevity of the BIOPROTECT formulation on treated surfaces, tests revealed that the presence of the BIOPROTECT formulation maintained the ability to inactivate SARS-CoV-2 to negligible levels.
  • Furthermore, test results from Rega demonstrated that the disks pretreated with the BIOPROTECT formulation averaged a 99.7% inactivation of the SARS-CoV-2 virus.
  • An official statement by Dr.Robert Galloand Dr. Christian Brchot on the two GVN Centers of Excellence independent verification of antimicrobial technology that eradicates SARS-CoV-2 on surfaces for more than six weeks can be found here .

Immunocore announces publication of preclinical data in Hepatology showing the potential of ImmTAV® bispecific molecules for functional cure of chronic hepatitis B

Retrieved on: 
Thursday, August 27, 2020
Medical specialties, Clinical medicine, Medicine, Immune system, Immunology, Infectious causes of cancer, Pandemics, Virus, Zoonoses, Hepatitis B, T cell, ImmTAC

Additionally, HBV-specific immune responses in people living with Hepatitis B are often exhausted, making it difficult for them to eliminate the infected cells.

Key Points: 
  • Additionally, HBV-specific immune responses in people living with Hepatitis B are often exhausted, making it difficult for them to eliminate the infected cells.
  • With this in mind, the team at Immunocore is utilising its immunemobilising monoclonal T cell receptors against virus (ImmTAV) platform to address these challenges.
  • ImmTAV and ImmTAC molecules resemble each other in appearance and function, although ImmTAV molecules are designed to specifically recognise and kill virally infected cells.
  • Immunocore is headquartered at Milton Park, Oxfordshire, UK, with offices in Conshohocken, Pennsylvania and Rockville, Maryland in the US.

Cocrystal Pharma Increases Previously Announced Bought Deal to $15.0 Million

Retrieved on: 
Thursday, August 27, 2020
Health, Articles, Medical specialties, Healthcare-associated infections, RTT, Pandemics, Virus, Zoonoses, Antiviral drug, Coronavirus, Influenza, Hepatitis

The closing of the offering is expected to occur on or about August 31, 2020, subject to satisfaction of customary closing conditions.

Key Points: 
  • The closing of the offering is expected to occur on or about August 31, 2020, subject to satisfaction of customary closing conditions.
  • The gross proceeds to Cocrystal, before deducting underwriting discounts and commissions and offering expenses and assuming no exercise of the underwriter's option to purchase additional common stock, are expected to be approximately$15.0 million.
  • The shares of common stock are being offered by the Company pursuant to a "shelf" registration statement on Form S-3 (File No.
  • Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, hepatitis C viruses, coronaviruses and noroviruses.

Cocrystal Pharma Announces $10.0 Million Bought Deal Offering

Retrieved on: 
Wednesday, August 26, 2020
Health, Articles, Medicine, Epidemiology, Pandemics, Virus, Zoonoses, Antiviral drug, Coronavirus, Influenza

The closing of the offering is expected to occur on or about August 31, 2020, subject to satisfaction of customary closing conditions.

Key Points: 
  • The closing of the offering is expected to occur on or about August 31, 2020, subject to satisfaction of customary closing conditions.
  • H.C. Wainwright & Co. is acting as the sole book-running manager for the offering.
  • The gross proceeds to Cocrystal, before deducting underwriting discounts and commissions and offering expenses and assuming no exercise of the underwriter's option to purchase additional common stock, are expected to be approximately$10.0 million.
  • Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, hepatitis C viruses, coronaviruses and noroviruses.

New Insights into How COVID-19 Causes Heart Damage

Retrieved on: 
Wednesday, August 26, 2020
Sarbecovirus, Respiratory diseases, Animal diseases, Zoonoses, Severe acute respiratory syndrome, Gladstone Institutes, COVID-19 drug repurposing research, Coronavirus disease

Heart damage is a major determinant of COVID-19 related deaths, and even patients who experience only mild COVID-19 symptoms exhibit signs of cardiac dysfunction several months after recovery.

Key Points: 
  • Heart damage is a major determinant of COVID-19 related deaths, and even patients who experience only mild COVID-19 symptoms exhibit signs of cardiac dysfunction several months after recovery.
  • A new study by scientists at Gladstone Institutes helps explain how SARS-CoV-2, the virus that causes COVID-19, inflicts damage on heart cells.
  • The team's findings, shared publicly on bioRxiv, show the virus's unexpected effects on the structure of heart cells in the lab, as well as in heart tissue from COVID-19 patients.
  • We believe they are unique to SARS-CoV-2 and could explain the prolonged heart damage seen in many COVID-19 patients."

Pilot Study to Investigate Use of Attune Medical’s ensoETM for COVID-19 Treatment Enrolls First Patient at Sharp Memorial Hospital in San Diego

Retrieved on: 
Wednesday, August 26, 2020
Health, Medical devices, Infectious diseases, Hospitals, General Health, Clinical trials, Biotechnology, Sarbecovirus, Animal diseases, Respiratory diseases, Zoonoses, Coronavirus disease, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome

The SARS-CoV-2 virus that causes COVID-19 may be particularly temperature sensitive, and elevated body temperatures could negatively impact its ability to enter cells.

Key Points: 
  • The SARS-CoV-2 virus that causes COVID-19 may be particularly temperature sensitive, and elevated body temperatures could negatively impact its ability to enter cells.
  • In the most critically ill patients with COVID-19, however, fever is often absent.
  • The study is led by pulmonologist and critical care physician David Willms, MD, building off of work on external warming by Drs.
  • Unlike surface warming devices, ensoETMs internal placement doesn't impede patient access during surgery and allows gastric decompression and administration of fluids and medications.

Celltrion Receives Korean MFDS Approval to Initiate Phase I Trial of COVID-19 Antiviral Antibody Treatment Candidate, CT-P59, in Patients

Retrieved on: 
Wednesday, August 26, 2020
Health, Infectious diseases, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Health, Articles, Clinical research, Pharmaceutical industry, Drug discovery, Design of experiments, Coronavirus disease, Zoonoses, Celltrion, Clinical trial, COVID-19 drug development, COVID-19 drug repurposing research, Celltrion Healthcare, COVID-191,2

Celltrion anticipates global pivotal study results from the Phase II and III trials in patients with mild symptoms, the Phase III trial in patients with moderate-to-severe COVID-19, and the prevention clinical trial, by the end of the year.

Key Points: 
  • Celltrion anticipates global pivotal study results from the Phase II and III trials in patients with mild symptoms, the Phase III trial in patients with moderate-to-severe COVID-19, and the prevention clinical trial, by the end of the year.
  • We have initiated an in-human global Phase I clinical trial of CT-P59 in mild COVID-19 patients and we plan to conduct further global Phase II and III trials in this patient group.
  • In addition, Celltrion plans to combine Phase II and III trials in patients with moderate-to-severe COVID-19 with the prevention clinical trials.
  • In July, Celltrion initiated a Phase I trial of CT-P59 in the UK following the approval of the clinical trial authorisation (CTA) application from the UK Medicines and Healthcare products Regulatory Agency (MHRA).

New portable air disinfection device rapidly kills coronavirus

Retrieved on: 
Wednesday, August 26, 2020
Articles, Health, Public health, Epidemiology, Infectious diseases, Zoonoses, Hand, Disinfectant, Infection prevention and control, Hand washing, Heating, ventilation, and air conditioning, Coronavirus

TORONTO, Aug. 26, 2020 /CNW/ - New hospital grade technology that rapidly kills airborne coronaviruses can make the air in office buildings safer and give employees and tenants the confidence to return to the workplace.

Key Points: 
  • TORONTO, Aug. 26, 2020 /CNW/ - New hospital grade technology that rapidly kills airborne coronaviruses can make the air in office buildings safer and give employees and tenants the confidence to return to the workplace.
  • The portable devices help close the gap in infection control protocol which had previously focused mostly on hand washing and the disinfection of surfaces.
  • "We now know that disinfecting the air is a critical step in reducing the transmission of airborne viruses like Covid-19," said Phillips.
  • HVAC system solutions are more expensive, and require travel back through the return air system, making them less effective.

HiFiBiO Therapeutics Submits IND Application for Fully Human SARS-CoV-2 Neutralizing Antibody for the Treatment of COVID-19 Patients

Retrieved on: 
Wednesday, August 26, 2020
Security, Manufacturing, Other Health, Nanotechnology, Other Science, Pharmaceutical, Research, Other Technology, Software, Networks, Internet, Infectious diseases, Data management, Science, Technology, Clinical trials, Biotechnology, Health, Other Manufacturing, Zoonoses, Medical specialties, Branches of biology, Medicine, Immunology, Antibodies, COVID-19, Sarbecovirus, Severe acute respiratory syndrome coronavirus 2, Neutralizing antibody, Coronavirus disease

HFB30132A is an anti-SARS-CoV-2 recombinant antibody engineered with specific sequences identified from the B cells of a COVID-19 convalescent patient.

Key Points: 
  • HFB30132A is an anti-SARS-CoV-2 recombinant antibody engineered with specific sequences identified from the B cells of a COVID-19 convalescent patient.
  • The antibody binds the viral spike protein with high affinity and has demonstrated potent neutralization of live virus infections in vitro and in vivo.
  • With this IND filing, we are now one step closer to delivering a breakthrough COVID-19 therapy to patients who need it most.
  • HiFiBiO Therapeutics and the HiFiBiO Therapeutics logo are trademarks of HiFiBiO and its affiliates.